UAE first to approve oral therapy for rare autoimmune disorder
The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide.
Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition.
The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life.
Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators.
Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation.
#WamNews https://t.co/hPemiKqXIA pic.twitter.com/MZHZM3gTg6
— WAM English (@WAMNEWS_ENG) July 8, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
a day ago
- Khaleej Times
France's Sanofi to acquire biotech firm Vicebio for $1.15 billion
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio. Following the acquisition, Vicebio's non-mRNA candidate vaccine for treating respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) will be added to Sanofi's range. The Vicebio deal includes a potential milestone payment of up to $450 million based on development and research achievements, and is expected to close in the fourth quarter of this year. Sanofi will also obtain "Molecular Clamp" technology aimed at enabling quicker development of fully liquid combination vaccines that can be stored at standard refrigeration temperatures, eliminating the need for freezing or freeze-drying. The British company is the latest in a string of acquisitions by Sanofi, which recently finalised an up to $9.5 billion deal for U.S.-based Blueprint Medicines Corporation. Sanofi said that the acquisition will not impact its annual guidance.
Dubai Eye
08-07-2025
- Dubai Eye
UAE first to approve oral therapy for rare autoimmune disorder
The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025
Khaleej Times
08-07-2025
- Khaleej Times
UAE becomes first country to approve oral drug for immune thrombocytopenia
The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people worldwide. With this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical needs. The approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of life. The decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatment s in line with the highest international standards and protocols. Developed by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of ITP. By increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.' Dr Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications. 'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.' She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'
